Gary Nachman
Stock Analyst at Raymond James
(3.56)
# 833
Out of 4,876 analysts
98
Total ratings
59.09%
Success rate
2.87%
Average return
Main Sectors:
Stocks Rated by Gary Nachman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABBV AbbVie | Maintains: Outperform | $220 → $227 | $186.79 | +21.53% | 15 | Apr 28, 2025 | |
| SDGR Schrödinger | Maintains: Outperform | $25 → $28 | $20.49 | +36.65% | 5 | Nov 13, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $275 → $298 | $318.25 | -6.36% | 7 | Nov 1, 2024 | |
| LENZ LENZ Therapeutics | Initiates: Outperform | $37 | $30.11 | +22.88% | 1 | Sep 27, 2024 | |
| ACHV Achieve Life Sciences | Initiates: Strong Buy | $20 | $3.51 | +469.80% | 1 | Sep 27, 2024 | |
| PCRX Pacira BioSciences | Maintains: Outperform | $41 → $37 | $23.60 | +56.78% | 13 | Jul 31, 2024 | |
| BLCO Bausch + Lomb | Initiates: Outperform | $19 | $12.07 | +57.42% | 1 | Jul 10, 2024 | |
| AMGN Amgen | Reinstates: Market Perform | n/a | $279.11 | - | 1 | Mar 28, 2024 | |
| SRRK Scholar Rock Holding | Initiates: Strong Buy | $30 | $35.48 | -15.45% | 5 | Mar 28, 2024 | |
| AQST Aquestive Therapeutics | Initiates: Outperform | $7 | $3.25 | +115.38% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $3 | $0.66 | +357.81% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $107.59 | - | 11 | Sep 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $4 | $8.13 | -50.80% | 5 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $30 | $9.55 | +214.14% | 4 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $67 | $39.78 | +68.43% | 2 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $32 | $3.74 | +755.61% | 1 | Feb 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $16 → $14 | $9.12 | +53.51% | 2 | Feb 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $43 → $40 | $9.28 | +331.03% | 8 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $11 → $10 | $16.56 | -39.61% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $30 | $18.76 | +59.91% | 2 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $810 → $750 | $3.58 | +20,849.72% | 2 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $15 → $8 | $6.41 | +24.80% | 2 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $20 → $21 | $23.18 | -9.40% | 5 | May 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $14 | $3.98 | +251.76% | 2 | Jun 14, 2018 |
AbbVie
Apr 28, 2025
Maintains: Outperform
Price Target: $220 → $227
Current: $186.79
Upside: +21.53%
Schrödinger
Nov 13, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $20.49
Upside: +36.65%
Alnylam Pharmaceuticals
Nov 1, 2024
Maintains: Outperform
Price Target: $275 → $298
Current: $318.25
Upside: -6.36%
LENZ Therapeutics
Sep 27, 2024
Initiates: Outperform
Price Target: $37
Current: $30.11
Upside: +22.88%
Achieve Life Sciences
Sep 27, 2024
Initiates: Strong Buy
Price Target: $20
Current: $3.51
Upside: +469.80%
Pacira BioSciences
Jul 31, 2024
Maintains: Outperform
Price Target: $41 → $37
Current: $23.60
Upside: +56.78%
Bausch + Lomb
Jul 10, 2024
Initiates: Outperform
Price Target: $19
Current: $12.07
Upside: +57.42%
Amgen
Mar 28, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $279.11
Upside: -
Scholar Rock Holding
Mar 28, 2024
Initiates: Strong Buy
Price Target: $30
Current: $35.48
Upside: -15.45%
Aquestive Therapeutics
Mar 28, 2024
Initiates: Outperform
Price Target: $7
Current: $3.25
Upside: +115.38%
Mar 28, 2024
Initiates: Outperform
Price Target: $3
Current: $0.66
Upside: +357.81%
Sep 29, 2023
Initiates: Market Perform
Price Target: n/a
Current: $107.59
Upside: -
Mar 3, 2023
Maintains: Market Perform
Price Target: $5 → $4
Current: $8.13
Upside: -50.80%
Mar 1, 2023
Maintains: Outperform
Price Target: $35 → $30
Current: $9.55
Upside: +214.14%
Feb 23, 2023
Maintains: Outperform
Price Target: $70 → $67
Current: $39.78
Upside: +68.43%
Feb 22, 2023
Maintains: Outperform
Price Target: $40 → $32
Current: $3.74
Upside: +755.61%
Feb 17, 2023
Downgrades: Market Perform
Price Target: $16 → $14
Current: $9.12
Upside: +53.51%
Nov 9, 2022
Maintains: Market Perform
Price Target: $43 → $40
Current: $9.28
Upside: +331.03%
Nov 7, 2022
Maintains: Market Perform
Price Target: $11 → $10
Current: $16.56
Upside: -39.61%
Nov 4, 2022
Maintains: Outperform
Price Target: $40 → $30
Current: $18.76
Upside: +59.91%
Aug 11, 2022
Maintains: Outperform
Price Target: $810 → $750
Current: $3.58
Upside: +20,849.72%
Aug 10, 2022
Maintains: Market Perform
Price Target: $15 → $8
Current: $6.41
Upside: +24.80%
May 11, 2020
Maintains: Market Perform
Price Target: $20 → $21
Current: $23.18
Upside: -9.40%
Jun 14, 2018
Maintains: Outperform
Price Target: $24 → $14
Current: $3.98
Upside: +251.76%